BioWorld MedTech

May 14, 2015

Financings: Glaukos files IPO, could be first public company in MIGS space

The latest development in the minimally invasive glaucoma surgical (MIGS) space comes from Glaukos (Laguna Hills, California) as the company has reportedly filed for an initial public offering (IPO) to raise $86 million. Read More

HRS annual Meeting : EP; HRS in danger of losing seat at the AMA RUC table

PLAC build-up: Cardio diagnostics broadening

Take a moment to complete critical reader survey

ResMed Fails to Hold SERVE: ResMed stock down after SERVE-HF misses its primary endpoint

Agreements/contracts: Abbott, GE Healthcare to integrate electrogram data

World in Review: W.L. Gore registers Excluder endoprosthesis in Australia

Patent Watch: USPTO issues patent allowance for Rosetta Cancer Origin Test

Briefly Noted

Product briefs

People in Places

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...